Article
Clinical and prognostic features of patients with detailed RAS/BRAF-mutant colorectal cancer in Japan.
BMC cancer - 7 May 2021
Ikoma Tatsuki, Shimokawa Mototsugu, Kotaka Masahito, Matsumoto Toshihiko, Nagai Hiroki, Boku Shogen, Shibata Nobuhiro, Yasui Hisateru, Satake Hironaga
Abstract excerpt
BACKGROUND: RAS/BRAFV600E mutations are the most remarkable oncogenic driver mutations in colorectal cancer (CRC) and play an important role in treatment selection. No data are available regarding the clinical and prognostic features of patients with detailed RAS/BRAFV600E-mutant metastatic CRC (mCRC) in Japan. METHODS: A total of 152 chemotherapy-naïve patients with mCRC were included in this study between...
Topics
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Colorectal Neoplasms
- Female
- GTP Phosphohydrolases
- Humans
- Male
- Membrane Proteins
- Middle Aged
